ERBB2 and breast cancer: Previous research demonstrated that as hormone-dependent, letrozole-sensitive breast cancer cells transition to a hormone-independent and letrozole-resistant phenotype, they utilize growth factor signaling pathways such as EGFR [5], p38/MAPK [4,15,16], and HER2 [17] as a mechanism of survival.